SCYNEXIS, Inc. continues to develop novel antifungal agents rooted in its proprietary fungerps platform, achieving FDA approval for ibrexafungerp and advancing second-generation candidate SCY-247 through Phase 1 trials. In 2025, the company reported a narrower net loss driven by licensing revenues from its deal with GlaxoSmithKline (GSK), balancing heavy R&D costs. SCYNEXIS's expanding pipeline and strategic licensing underpin its efforts to address serious fungal infections, though regulatory complexities and financial sustainability remain key challenges to monitor.